95. ASCO GU 2024 Spectacular (Part 2)

While Josh and Michael enjoy a good rambling, meandering podcast as much as the next guy, we made a promise to keep our coverage of the ASCO GU 2024 conference short and sweet. So, as promised, here is the second - and final - episode of our miniseries. For a change of pace, one of our studies involves the adjuvant use of immunotherapy! Specifically, AMBASSADOR looks at pembrolizumab in patients with early urothelial cancer, a patient cohort that is crying out for more effective treatments for early-stage disease. Meanwhile, Josh tries to "BRCAAway" from our comfort zone by discussing the latest trial examining the use of PARP inhibitors in metastatic castration-resistant prostate cancer. Yes, we'll show ourselves out now.

Links to studies discussed in this episode (subscription may be required):

AMBASSADOR (courtesy of ASCO Daily news): https://ascopost.com/news/january-2024/ambassador-pembrolizumab-in-muscle-invasive-and-locally-advanced-urothelial-carcinoma/#:~:text=AMBASSADOR%20(A031501)%20is%20a%20randomized,and%20locally%20advanced%20urothelial%20carcinoma.

BRCAAway (courtesy of urotoday.com): https://www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137781-asco-2022-brcaaway-a-randomized-phase-2-trial-of-abiraterone-olaparib-or-abiraterone-olaparib-in-patients-with-mcrpc-with-dna-repair-defects.html

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.